

# Jaap Verweij

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/10407725/jaap-verweij-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

121  
papers

28,390  
citations

55  
h-index

128  
g-index

128  
ext. papers

30,569  
ext. citations

7.1  
avg, IF

6.13  
L-index

#	Paper	IF	Citations
121	Unequal Access to Newly Registered Cancer Drugs Leads to Potential Loss of Life-Years in Europe. <i>Cancers</i> , <b>2020</b> , 12,	6.6	10
120	Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics. <i>Breast Cancer Research and Treatment</i> , <b>2019</b> , 177, 383-393	4.4	10
119	Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2018</b> , 4, 483-492	13.4	142
118	Surrogate endpoints in advanced sarcoma trials: a meta-analysis. <i>Oncotarget</i> , <b>2018</b> , 9, 34617-34627	3.3	5
117	Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose Levels. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1713-1720	2.2	88
116	Health policy: Affordability of drugs used in oncology health care. <i>Nature Reviews Clinical Oncology</i> , <b>2016</b> , 13, 331-2	19.4	4
115	Development and validation of prognostic nomograms for metastatic gastrointestinal stromal tumour treated with imatinib. <i>European Journal of Cancer</i> , <b>2015</b> , 51, 852-60	7.5	21
114	miR-634 restores drug sensitivity in resistant ovarian cancer cells by targeting the Ras-MAPK pathway. <i>Molecular Cancer</i> , <b>2015</b> , 14, 196	42.1	45
113	4Hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes. <i>British Journal of Clinical Pharmacology</i> , <b>2015</b> , 80, 560-8	3.8	16
112	Recurrence of melanoma following T cell treatment: continued antigen expression in a tumor that evades T cell recruitment. <i>Molecular Therapy</i> , <b>2015</b> , 23, 396-406	11.7	18
111	Determining the optimal dose in the development of anticancer agents. <i>Nature Reviews Clinical Oncology</i> , <b>2014</b> , 11, 272-81	19.4	111
110	Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study. <i>European Journal of Cancer</i> , <b>2014</b> , 50, 2040-9	7.5	86
109	Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. <i>Lancet Oncology</i> , <b>2014</b> , 15, 415-23	21.7	629
108	Dose-response relationship in phase i clinical trials: a European Drug Development Network (EDDN) Collaboration Study. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 5663-71	12.9	11
107	Dispelling the myths around cancer care delivery: It's not all about costs. <i>Journal of Cancer Policy</i> , <b>2014</b> , 2, 22-29	1	23
106	The effect of baseline morphology and its change during treatment on the accuracy of Response Evaluation Criteria in Solid Tumours in assessment of liver metastases. <i>European Journal of Cancer</i> , <b>2014</b> , 50, 972-80	7.5	15
105	Pazopanib, a new therapy for metastatic soft tissue sarcoma. <i>Expert Opinion on Pharmacotherapy</i> , <b>2013</b> , 14, 929-35	4	33

104	Modifying phase I methodology to facilitate enrolment of molecularly selected patients. <i>European Journal of Cancer</i> , <b>2013</b> , 49, 1515-20	7.5	13
103	A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas. <i>European Journal of Cancer</i> , <b>2012</b> , 48, 3036-44	7.5	105
102	Danusertib, an aurora kinase inhibitor. <i>Expert Opinion on Investigational Drugs</i> , <b>2012</b> , 21, 383-93	5.9	45
101	Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. <i>Lancet Oncology, The</i> , <b>2012</b> , 13, 1045-54	21.7	312
100	Moving molecular targeted drug therapy towards personalized medicine: issues related to clinical trial design. <i>Molecular Oncology</i> , <b>2012</b> , 6, 196-203	7.9	22
99	Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 282-90	2.2	571
98	Leveling the playing field: bringing development of biomarkers and molecular diagnostics up to the standards for drug development. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 1515-23	12.9	37
97	Reply to F.L. Opdam et al. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 465-465	2.2	
96	Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 996-1004	2.2	55
95	A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 5780-7	12.9	80
94	Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 3170-9	12.9	95
93	A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 2687-94	12.9	57
92	Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 4458-64	12.9	143
91	Clinical trials in drug development: a minimalistic approach. <i>Current Opinion in Oncology</i> , <b>2012</b> , 24, 332-7	4.2	2
90	Phase I and pharmacokinetic (PK) study of pazopanib (P) in combination with two schedules of ifosfamide (I) in patients (pts) with advanced solid tumors (STs).. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 2593-2593	2.2	2
89	Tumor volume as an alternative response measurement for imatinib treated GIST patients. <i>PLoS ONE</i> , <b>2012</b> , 7, e48372	3.7	29
88	Prediction of early death among patients (pts) enrolled in phase I trials: Development and validation of a new model based on platelet count and albumin level.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 2540-2540	2.2	
87	Early response to neoadjuvant chemotherapy (NAC) in combination with regional hyperthermia (RHT) to predict long-term survival for adult-type high-risk soft tissue sarcoma (HR-STs): Results of the EORTC-ESHO intergroup phase III study.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 10054-10054	2.2	

86	Single-dimension CT measurements with RECIST 1.1 to evaluate liver metastases in GIST patients on imatinib.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 10091-10091	2.2	1
85	Growth modulation index (GMI) as a metric of clinical benefit assessment among advanced soft tissue sarcoma (ASTS) patients receiving trabectedin as salvage therapy.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 10013-10013	2.2	
84	Adjuvant treatment of gastrointestinal stromal tumor: the proof, the pro, and the practice. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2012</b> , 659-62	7.1	
83	Drug transporters and imatinib treatment: implications for clinical practice. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 406-15	12.9	119
82	Effect of omeprazole on the pharmacokinetics and toxicities of irinotecan in cancer patients: a prospective cross-over drug-drug interaction study. <i>European Journal of Cancer</i> , <b>2011</b> , 47, 831-8	7.5	12
81	Effects of methimazole on the elimination of irinotecan. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2011</b> , 67, 231-6	3.5	6
80	Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 7156-63	12.9	75
79	Early Clinical Trials with Cytotoxic Agents <b>2011</b> , 335-345		
78	DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours. <i>Histopathology</i> , <b>2010</b> , 57, 259-70	7.3	136
77	Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). <i>European Journal of Cancer</i> , <b>2010</b> , 46, 72-83	7.5	189
76	Future treatment of soft tissue sarcomas will be driven by histological subtype and molecular aberrations. <i>European Journal of Cancer</i> , <b>2010</b> , 46, 863-8	7.5	36
75	Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation. <i>European Journal of Cancer</i> , <b>2010</b> , 46, 3016-21	7.5	60
74	Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. <i>Lancet Oncology</i> , <b>2010</b> , 11, 561-70	21.7	467
73	Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 3126-32	2.2	523
72	Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 5584-90	12.9	94
71	Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 3969-74	2.2	80
70	Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors. <i>Molecular Cancer Therapeutics</i> , <b>2009</b> , 8, 1430-7	6.1	33
69	Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 5094-101	2.2	89

68	Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 4169-76	2.2	39
67	Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 5869-77	12.9	46
66	Cell cycle/apoptosis molecule expression correlates with imatinib response in patients with advanced gastrointestinal stromal tumors. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 4191-8	12.9	55
65	Cancer clinical trial outcomes: any progress in tumour-size assessment?. <i>European Journal of Cancer</i> , <b>2009</b> , 45, 225-7	7.5	30
64	Individual patient data analysis to assess modifications to the RECIST criteria. <i>European Journal of Cancer</i> , <b>2009</b> , 45, 248-60	7.5	144
63	Lifestyle habits as a contributor to anti-cancer treatment failure. <i>European Journal of Cancer</i> , <b>2008</b> , 44, 374-82	7.5	19
62	Distribution and prognostic value of histopathologic data and immunohistochemical markers in gastrointestinal stromal tumours (GISTs): An analysis of the EORTC phase III trial of treatment of metastatic GISTs with imatinib mesylate. <i>European Journal of Cancer</i> , <b>2008</b> , 44, 1855-60	7.5	30
61	No risk, no funS challenges for the oncology phase I clinical trial time-performance. <i>European Journal of Cancer</i> , <b>2008</b> , 44, 2600-7	7.5	10
60	Drug Insight: gastrointestinal stromal tumors (GIST)--the solid tumor model for cancer-specific treatment. <i>Nature Clinical Practice Oncology</i> , <b>2008</b> , 5, 102-11		70
59	Effect of cigarette smoking on imatinib in patients in the soft tissue and bone sarcoma group of the EORTC. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 8308-13	12.9	19
58	Other endpoints in screening studies for soft tissue sarcomas. <i>Oncologist</i> , <b>2008</b> , 13 Suppl 2, 27-31	5.7	19
57	A phase II study of gefitinib for patients with advanced HER-1 expressing synovial sarcoma refractory to doxorubicin-containing regimens. <i>Oncologist</i> , <b>2008</b> , 13, 467-73	5.7	47
56	Decrease of CD117 expression as possible prognostic marker for recurrence in the resected specimen after imatinib treatment in patients with initially unresectable gastrointestinal stromal tumors: a clinicopathological analysis. <i>Anti-Cancer Drugs</i> , <b>2008</b> , 19, 607-12	2.4	14
55	GIST as the model of paradigm shift towards targeted therapy of solid tumors: update and perspective on trial design. <i>Advances in Experimental Medicine and Biology</i> , <b>2008</b> , 610, 144-54	3.6	2
54	Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxel. <i>Oncologist</i> , <b>2007</b> , 12, 291-300	5.7	51
53	Improved insight into resistance mechanisms to imatinib in gastrointestinal stromal tumors: a basis for novel approaches and individualization of treatment. <i>Oncologist</i> , <b>2007</b> , 12, 719-26	5.7	55
52	Irinotecan chemotherapy during valproic acid treatment: pharmacokinetic interaction and hepatotoxicity. <i>Cancer Biology and Therapy</i> , <b>2007</b> , 6, 1368-74	4.6	16
51	Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 3111-50	2.2	209

50	Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 2719-26	2.2	91
49	Alternative drug formulations of docetaxel: a review. <i>Anti-Cancer Drugs</i> , <b>2007</b> , 18, 95-103	2.4	159
48	Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. <i>European Journal of Cancer</i> , <b>2007</b> , 43, 308-15	7.5	41
47	Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005. <i>European Journal of Cancer</i> , <b>2007</b> , 43, 974-8	7.5	85
46	A phase I study of a new nucleoside analogue, OSI-7836, using two administration schedules in patients with advanced solid malignancies. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 2841-8	12.9	6
45	Complementary and alternative medicine during cancer treatment: beyond innocence. <i>Oncologist</i> , <b>2006</b> , 11, 732-41	5.7	120
44	Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. <i>Lancet, The</i> , <b>2006</b> , 368, 1329-38	4.0	2004
43	Practical aspects of managing gastrointestinal stromal tumors. <i>Clinical Colorectal Cancer</i> , <b>2006</b> , 6 Suppl 1, S18-23	3.8	4
42	Role of pharmacogenetics in irinotecan therapy. <i>Cancer Letters</i> , <b>2006</b> , 234, 90-106	9.9	78
41	KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. <i>European Journal of Cancer</i> , <b>2006</b> , 42, 1093-103	7.5	701
40	Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG). <i>European Journal of Cancer</i> , <b>2006</b> , 42, 2277-85	7.5	82
39	Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. <i>Cancer Biology and Therapy</i> , <b>2005</b> , 4, 747-52	4.6	161
38	Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. <i>European Journal of Cancer</i> , <b>2005</b> , 41, 1751-7	7.5	298
37	Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2005</b> , 55, 379-386	3.5	164
36	Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 1504-11	12.9	80
35	Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 889-98 <sup>2</sup>	2.2	24
34	Phase I and pharmacokinetic study of the dolastatin 10 analogue TZT-1027, given on days 1 and 8 of a 3-week cycle in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 3806-13	12.9	61
33	Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 5795-804	2.2	239

32	Using single-agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard care. <i>Oncologist</i> , <b>2005</b> , 10, 833-41	5.7	75
31	Paclitaxel repackaged in an albumin-stabilized nanoparticle: handy or just a dandy?. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 7765-7	2.2	29
30	The epothilone dilemma. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 9048-50	2.2	28
29	Imatinib and gastrointestinal stromal tumors: Where do we go from here?. <i>Molecular Cancer Therapeutics</i> , <b>2005</b> , 4, 495-501	6.1	36
28	New targets in oncology drug development. <i>Clinical Advances in Hematology and Oncology</i> , <b>2005</b> , 3, 754-5.6		
27	Targeted therapy: ready for prime time?. <i>Cancer Treatment and Research</i> , <b>2004</b> , 120, 1-15	3.5	3
26	KIT and PDGF as targets. <i>Cancer Treatment and Research</i> , <b>2004</b> , 120, 117-27	3.5	2
25	Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes. <i>Journal of the National Cancer Institute</i> , <b>2004</b> , 96, 1585-92	9.7	98
24	Factors affecting cytochrome P-450 3A activity in cancer patients. <i>Clinical Cancer Research</i> , <b>2004</b> , 10, 8341-50	12.9	107
23	Simultaneous analysis of docetaxel and the formulation vehicle polysorbate 80 in human plasma by liquid chromatography/tandem mass spectrometry. <i>Analytical Biochemistry</i> , <b>2004</b> , 324, 276-84	3.1	67
22	Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. <i>Lancet, The</i> , <b>2004</b> , 364, 1127-34	4.0	1354
21	Clinical studies of camptothecin and derivatives. <i>The Alkaloids Chemistry and Biology</i> , <b>2003</b> , 60, 1-50	4.8	7
20	Clinical trial design for target specific anticancer agents. <i>Investigational New Drugs</i> , <b>2003</b> , 21, 243-50	4.3	33
19	Pharmacological effects of formulation vehicles : implications for cancer chemotherapy. <i>Clinical Pharmacokinetics</i> , <b>2003</b> , 42, 665-85	6.2	457
18	Metastatic Soft Tissue Sarcoma in Adults. <i>American Journal of Cancer</i> , <b>2003</b> , 2, 211-221		19
17	Role of imatinib mesylate (Gleevec/Glivec) in gastrointestinal stromal tumors. <i>Expert Review of Anticancer Therapy</i> , <b>2003</b> , 3, 757-66	3.5	11
16	Disposition of docosahexaenoic acid-paclitaxel, a novel taxane, in blood: in vitro and clinical pharmacokinetic studies. <i>Clinical Cancer Research</i> , <b>2003</b> , 9, 151-9	12.9	39
15	Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions. <i>Journal of Clinical Oncology</i> , <b>2002</b> , 20, 574-81	2.2	69

14	Determination of the docetaxel vehicle, polysorbate 80, in patient samples by liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2002</b> , 773, 183-90	3.2	32
13	Effects of St. John's wort on irinotecan metabolism. <i>Journal of the National Cancer Institute</i> , <b>2002</b> , 94, 1247-9	9.7	297
12	Preclinical evaluation of alternative pharmaceutical delivery vehicles for paclitaxel. <i>Anti-Cancer Drugs</i> , <b>2002</b> , 13, 767-75	2.4	21
11	Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. <i>European Journal of Cancer</i> , <b>2002</b> , 38 Suppl 5, S83-7	7.5	170
10	Influence of Cremophor EL on the bioavailability of intraperitoneal paclitaxel. <i>Clinical Cancer Research</i> , <b>2002</b> , 8, 1237-41	12.9	62
9	Mechanism-based pharmacokinetic model for paclitaxel. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 4065-73	2.2	118
8	Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2001</b> , 47, 309-18	3.5	105
7	Role of formulation vehicles in taxane pharmacology. <i>Investigational New Drugs</i> , <b>2001</b> , 19, 125-41	4.3	240
6	Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. <i>Lancet, The</i> , <b>2001</b> , 358, 1421-3	40	1091
5	Inter-relationships of paclitaxel disposition, infusion duration and cremophor EL kinetics in cancer patients. <i>Anti-Cancer Drugs</i> , <b>2000</b> , 11, 331-7	2.4	44
4	Clinical studies in the development of new anticancer agents exhibiting growth inhibition in models: facing the challenge of a proper study design. <i>Critical Reviews in Oncology/Hematology</i> , <b>2000</b> , 34, 83-8	7	20
3	New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. <i>Journal of the National Cancer Institute</i> , <b>2000</b> , 92, 205-16	9.7	13624
2	Quantitation of Cremophor EL in human plasma samples using a colorimetric dye-binding microassay. <i>Analytical Biochemistry</i> , <b>1998</b> , 255, 171-5	3.1	41
1	Linearized colorimetric assay for cremophor EL: application to pharmacokinetics after 1-hour paclitaxel infusions. <i>Analytical Biochemistry</i> , <b>1998</b> , 261, 198-202	3.1	21